Labcorp Reaffirms 2026 Outlook, Unveils 5-8% Revenue Growth Target Through 2029
LH sits 32% above its 52-week low of $244.52.
Summary
Labcorp reaffirmed its full-year 2026 adjusted EPS guidance of $18.10-$18.55 and revenue of $14.71B-$14.83B, matching the range issued on July 30. The new information is the long-term outlook: management projects revenue CAGR of 5-8% and adjusted EPS CAGR of 8.5-12% through 2029, implying sustained above-market growth. The company cited specialty testing (oncology, neurology, autoimmune, women's health), personalized health solutions, and AI/robotics as key drivers. This follows the July 30 guidance raise and the September 8 MLM Medical Labs acquisition, reinforcing the growth narrative. The Investor Day presentation today provides the platform for these targets, which are more specific than prior disclosures.
Updates
· Benzinga — Shares fell 3.73% to $309.12 on the day. The company also highlighted four strategic priorities: specialty testing, health system and pharma partnerships, personalized health, and AI/robotics integration.
At the time of this announcement, LH was trading at $322.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $26B. The 52-week trading range was $244.52 to $341.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.